Ototoxicity after platinum‑based chemotherapy in the treatment of melanotic neuroectodermal tumour of infancy

Abstract

Melanotic neuroectodermal tumor of infancy (MNTI) is a rare infantile tumor that originates from mesenchymal-neuroectodermal cells, the treatment of which uses platinum derivatives that can affect hearing loss. The present study evaluated the long-term effects of ototoxicity following chemotherapy with cisplatin, vincristine, cyclophosphamide, teniposide and adriamycin in a 10-year-old patient after surgical removal of a MNTI tumor at the age of 8 months. Audiometric tests (high-frequency tonal audiometry, speech audiometry, speech acoustics, tympanometry and absorbance measurements) were performed during a 10-year follow-up after receiving chemotherapy. Hearing disorders in the high-frequency range (6,000 to 16,000 Hz range) were demonstrated for both ears, indicating that these may be the long-term effects of chemotherapy with use of platinum compounds during the treatment of infants. Case study This case study presents a long-term ototoxic effects after chemotherapy with cisplatin, vincristine, cyclophosphamide, teniposide and adriamycin in a 10-year-old female patient, who was administered this combination of drugs before and after surgical removal of MNTI at the age of 8 months. A female patient aged three months was admitted to the Department of Haematology and Paediatric Oncology of the Karol Jonscher Clinical Hospital in Poznan with a mixed mesenchymal-neuroectodermal MNTI, a solid tumor within the alveolar ridge. Histopathological examination

The Role of Chemotherapy in Management of Inoperable, Metastatic and/or Recurrent Melanotic Neuroectodermal Tumor of Infancy—Own Experience and Systematic Review

“…Among them, two cases were duplicates [16,28] and four cases were excluded due to unclear histology [29][30][31][32]. Eight cases were excluded due to lack of information on the cytostatic drugs administered to patients [16,[33][34][35][36] or no data on the response to CHT [37,38]. In two patients, CHT was combined with RTX; in those cases, therefore, the response to CHT was impossible to define [23,39].…”

Applications of the Grading Scales for the Detection of Ototoxicity in Children after Treatment of Neuroblastoma and Extracranial Germinal Tumor

“…54.2% of these patients were treated with one of the cytostatic drugs (cisplatin or carboplatin) and 35.4% with both. Hearing should be tested during or immediately after chemotherapy in children [Hojan-Jezierska et al, 2020].…”